Fremanezumab in Children and Adolescents with Episodic Migraine
Among children and adolescents with episodic migraine, fremanezumab resulted in greater reductions in the number of migraine days and headache days than placebo. Injection-site erythema was the most common adverse event with fremanezumab. Longer follow-up is required to further understand the efficacy and safety of the drug in this population. (Funded by Teva Pharmaceuticals; ClinicalTrials.gov number, NCT04458857.).
Authors
- Petra Bittigau (ORCID: https://orcid.org/0000-0002-6989-5223)
- Yael Carmeli Schwartz
- P. Barbanti
- Andrew D. Hershey (ORCID: https://orcid.org/0000-0002-1598-7536)
- Verena Ramirez Campos
- Christina L. Szperka (ORCID: https://orcid.org/0000-0003-4786-8889)
- Juline Bryson
- Yoel Kessler
- Xiaoping Ning
- Steve Barash
- Patricia Pozo-Rosich
Institutions
- Universitat Autònoma de Barcelona (ES)
- Cincinnati Children's Hospital Medical Center (US)
- Children's Hospital of Philadelphia (US)
- Vita-Salute San Raffaele University (IT)
- San Raffaele University of Rome (IT)
- Vall d'Hebron Institut de Recerca (ES)
- Teva Pharmaceuticals (Israel) (IL)
- IRCCS Ospedale San Raffaele (IT)
- Teva Pharmaceuticals (United States) (US)
- University of Cincinnati (US)
- Charité - Universitätsmedizin Berlin (DE)
- University of Pennsylvania (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1056/nejmoa2504546
- Citations
- 4
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 132.49